Bone Safety of Dolutegravir-Containing Regimens in People Living with HIV: Results from a Real-World Cohort.
Bonfanti PaoloAndrea De VitoElena Delfina RicciBarbara MenzaghiGiancarlo OrofinoNicola SquillaceChiara MolteniGiuseppe Vittorio De SocioElena SalomoniBenedetto Maurizio CelesiaBarbara MenzaghiValeria ColomboGiordano MadedduPublished in: Infection and drug resistance (2020)
Dolutegravir-containing regimens could reduce the negative impact of antiretroviral therapy on bone, especially in patients with low BMD.